Lakmal W. Boteju

TL;DR: The primary objective was to establish the maximum tolerated dose of CPI-613 (as assessed by dose-limiting toxicities) in patients with newly diagnosed metastatic pancreatic adenocarcinoma.

TL;DR: In vitro metabolic studies using liver S9 demonstrated that CPI-613 undergoes both phase 1 (oxidation) and phase 2 (glucuronidation) transformations, and CYP450 reaction phenotyping and inhibition data suggested that multiple CYP isozymes (2C8 and 3A4, along with minor contributions by 2C9 and 2C19) were involved inCPI-613 metabolism and sulfoxide formation.

TL;DR: In this article, a redox-modulating compound, such as a lipoic acid derivative, chemically bonded to an anti-proliferation agent such as gemcitabine, is described.

TL;DR: In this article, a pharmaceutical composition is constructed from a compound comprising a fatty acid, or analogue thereof, conjugated to at least one polymer, non-polymer, or lipid-based particle and/or one therapeutic, imaging, or diagnostic agent, modulates the binding affinity of the compound to a carrier molecule in the blood of warm-blooded animals in such a way as to modulate the circulation time of the pharmaceutical composition, and consequently the penetration and distribution of the compounds into a tumor mass, as well as demonstrate selective uptake and transport into a specific organelle

TL;DR: In this paper, the authors describe methods and compositions for treating a disease or disorder by orally administering to a patient in need thereof 6,8-bis-benzylthio-octanoic acid or a pharmaceutically acceptable salt thereof, optionally in combination with a second therapeutic agent.